As a supplement to its well-known quarterly outlook report, Biomedtracker presents a longer-term look at some key late-stage drugs projected to hit the market in 2024. These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.
